Buscar

02/05/2023 A multicenter case-control study comparing sun exposure habits and use of photoprotection measures in patients diagnosed with different types of skin cancer
Navarro-Bielsa A., Gracia-Cazaña T., Almagro M., De la Fuente-Meira, S, Florez Á., Yélamos O., Montero-Vilchez T., González-Cruz C., Diago A., Abadías-Granado I., Fuentelsaz V., Colmenero M., Banuls, J, Arias-Santiago S., Buendía-Eisman A., Almenara-Blasco M., Gil-Pallares P., Gilaberte Y.. A multicenter case-control study comparing sun exposure habits and use of photoprotection measures in patients diagnosed with different types of skin cancer. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE. 2023; 39(5)DOI:10.1111/phpp.12878. PMID:37130164. IF:2.500(Q2/4D).
01/05/2023 Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts
Carrascosa, JM, Vilarrasa, E, Belinchon, I, Herranz, P, Crespo, J, Guimera, F, Olveira, A. Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts. Actas Dermo-Sifiliograficas. 2023; 114(5)DOI:10.1016/j.ad.2023.01.004. PMID:36720362. IF:(Q/D).
20/04/2023 Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey
Quirke-McFarlane, S, Weinman, J, Cook, ES, Yiu, ZZN, Dand, N, Langan, SM, Bechman, K, Tsakok, T, Mason, KJ, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Barbosa, IA, Bachelez, H, Capon, F, Contreras, CR, De La Cruz, C, Di Meglio, P, Gisondi, P, Jullien, D, Lambert, J, Naldi, L, Puig, L, Spuls, P, Torres, T, Warren, RB, Waweru, H, Galloway, JB, Griffiths, CEM, Barker, JN, Norton, S, Smith, CH, Mahil, SK. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(5)DOI:10.1093/bjd/ljac144. PMID:36763806. IF:11.000(Q1/1D).
05/04/2023 Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale
Montero-Vilchez, T, Garces, JR, Rodriguez-Prieto, MA, Ruiz-Salas, V, de Eusebio-Murillo, E, Minano-Medrano, R, Escutia-Munoz, B, Gonzalez-Sixto, B, Artola-Igarza, JL, Alfaro-Rubio, A, Redondo, P, Delgado-Jimenez, Y, Sanchez-Schmidt, JM, Allende-Markixana, I, Alonso-Pacheco, ML, Garcia-Bracamonte, B, de la Cueva-dobao, P, Navarro-Tejedor, R, Ciudad-Blanco, C, Carnero-Gonzalez, L, Vazquez-Veiga, H, Cano-Martinez, N, Vilarrasa, E, Sanchez-Sambucety, P, Lopez-Estebaranz, JL, Botella-Estrada, R, Feal-Cortizas, JC, Martorell-Calatayud, A, Gil, P, Morales-Gordillo, V, Toll-Abello, A, Ocerin-Guerra, I, Mayor-Arenal, M, Suarez-Fernandez, R, Sainz-Gaspar, L, Descalzo, MA, Garcia-Doval, I, Sanmartin-Jimenez, O. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(8)DOI:10.1111/jdv.19056. PMID:36950898. IF:8.500(Q1/1D).
01/04/2023 Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years
Falkenhain-Lopez, D, Muniesa, C, Estrach, MT, Morillo-Andujar, M, Penate, Y, Acebo, E, Pujol, RM, Garcia-Muret, MP, Machan, S, Medina, S, Botella-Estrada, R, de Misa, RF, Blanes, M, Florez, A, Perez-Paredes, G, Izu, R, Yanguas, I, Silva-Diaz, E, Perez-Ferriols, A, Prieto-Torres, L, Zayas, A, Parera-Amer, ME, Perez, A, Aspe, L, Roman, C, Sanchez-Caminero, MP, Bassas-Vila, J, Dominguez-Aunon, JD, Calzado, L, Navedo, M, Ortiz-Prieto, A, Servitje, O, Polo-Rodriguez, I, Torres, I, Hernandez-Hernandez, MN, Mitxelena-Eceiza, J, Garcia-Vazquez, A, Garcia-Doval, I, Ortiz-Romero, PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermo-Sifiliograficas. 2023; 114(4)DOI:10.1016/j.ad.2022.11.013. PMID:36848951. IF:(Q/D).
15/03/2023 Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care
Escale-Besa, A, Yelamos, O, Vidal-Alaball, J, Fuster-Casanovas, A, Catalina, QM, Borve, A, Aguilar, RAE, Fusta-Novell, X, Cubiro, X, Rafat, ME, Lopez-Sanchez, C, Marin-Gomez, FX. Exploring the potential of artificial intelligence in improving skin lesion diagnosis in primary care. Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-31340-1. PMID:36922556. IF:3.800(Q1/2D).
10/03/2023 Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023)
Egeberg A., Merola J.F., Schaekel, K, Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths, CEM. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes (vol 9, 1092688, 2023). Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1171132. PMID:36974067. IF:3.100(Q1/2D).
22/02/2023 Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis, G, Warren, RB, Strober, B, Blauvelt, A, Puig, L, Morita, A, Gooderham, M, Korber, A, Vanvoorden, V, Wang, M, de Cuyper, D, Madden, C, Gomez, NN, Lebwohl, M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(3)DOI:10.1093/bjd/ljac089. PMID:36751950. IF:11.000(Q1/1D).
01/02/2023 BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis
Fusta-Novell, X, Garcia-Herrera, A, Yelamos, O. BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2021.10.022. PMID:36216154. IF:(Q/D).
01/01/2023 Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives
Camina-Conforto, G, Mateu-Arrom L., López-Ferrer A., Puig L.. Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives. Patient Preference and Adherence. 2023; 17DOI:10.2147/PPA.S350760. PMID:37408843. IF:2.000(Q2/4D).
01/01/2023 Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain
Artime E., Serra E., Mert C., Díaz-Cerezo S., Huete T., Hernández-Subirá I., Lledo-Bryant L., Sicras-Mainar A.. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain. Actas Dermo-Sifiliograficas. 2023; 114(1)DOI:10.1016/j.ad.2022.08.025. PMID:36368579. IF:(Q/D).
01/01/2023 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober B., Paul C., Blauvelt A., Thaçi D., Puig L., Lebwohl M., White K., Vanvoorden V., Deherder D., Gomez N.N., Eyerich K.. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(3)DOI:10.1016/j.jaad.2023.04.063. PMID:37182701. IF:12.800(Q1/1D).
01/01/2023 PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
Langenbruch A., Mohr N., Andrees V., Kessens I., Reich A., Czarnecka-Operacz M., Puig L., Dauden E., Iversen L., Augustin M.. PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries. ACTA DERMATO-VENEREOLOGICA. 2023; 103DOI:10.2340/actadv.v103.6532. PMID:37649411. IF:3.500(Q1/3D).
01/01/2023 Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Pereyra-Rodríguez J.-J., Herranz P., Ruiz-Villaverde R., Elosua-González M., Galán-Gutiérrez M., Figueras-Nart I., Miquel J., de la Cueva P., Serra-Baldrich E., Munera-Campos M., Melé-Ninot G., Expósito-Serrano V., Perez B., Serrano A., Ortiz de Frutos J.F., Armario-Hita J.C.. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(9)DOI:10.1093/ced/llad153. PMID:37098171. IF:3.700(Q1/2D).
01/01/2023 Genetic and Epigenetic Mechanisms of Psoriasis
Mateu-Arrom L., Puig L.. Genetic and Epigenetic Mechanisms of Psoriasis. Genes. 2023; 14(8)DOI:10.3390/genes14081619. PMID:37628670. IF:2.800(Q2/5D).
01/01/2023 The biological basis of disease recurrence in psoriasis
Carmona-Rocha E., Puig L.. The biological basis of disease recurrence in psoriasis. Italian Journal of Dermatology and Venereology. 2023; 158(4)DOI:10.23736/S2784-8671.23.07583-7. PMID:37404193. IF:1.800(Q3/6D).
01/01/2023 Diversity in the clinical presentation of generalized pustular psoriasis (GPP): A series of case vignettes from around the world
Choon S.E., Elewski B.E., Fujita H., Geng S., van de Kerkhof P., Mburu S., Puig L., Romiti R., Venturini M.. Diversity in the clinical presentation of generalized pustular psoriasis (GPP): A series of case vignettes from around the world. EXPERIMENTAL DERMATOLOGY. 2023; 32(8)DOI:10.1111/exd.14794. PMID:36999936. IF:3.500(Q1/3D).
01/01/2023 Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study
Castellanos-Gonzalez M., Bris B.B., Marsol I.B., Campos M.M., Ruiz-Villaverde R., Llorente C.P., Nuno-Gonzalez A., Sánchez J.T., Mur E.C., García R.G., Alonso A.B., Español G.A., García Y.H., Schmidt J.M.S., Sánchez M.A., Crespo E.R., Alonso E.D.L.H., Gallo-Pineda G., Izquierdo J.A.A., Varillas-Delgado D.. Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; 21(7)DOI:10.1111/ddg.15089. PMID:37218533. IF:5.600(Q1/1D).
01/01/2023 Prognostic factors for satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: A multicentric cohort study
Marti-Marti I., Podlipnik S., Cañueto J., Ferrándiz-Pulido C., Deza G., Sanmartín O., Jaka A., Beà-Ardèbol S., Botella-Estrada R., Redondo P., Turrión-Merino L., Ruiz-Salas V., Masferrer E., Yébenes M., Sánchez-Schmidt J.-M., Gracia-Darder I., Altemir-Vidal A., Aguayo-Ortiz R.S., Becerril S., Bodet-Castillo D., Leal L., Fuente M.J., Moreno-Arrones O.M., Abril-Pérez C., Tomás-Velázquez A., Sandoval-Clavijo A., Toll A.. Prognostic factors for satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: A multicentric cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(1)DOI:10.1016/j.jaad.2023.02.048. PMID:36907554. IF:12.800(Q1/1D).
01/01/2023 [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis [Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave]
Ruiz-Villaverde R., Galán-Gutiérrez M., Llamas-Velasco M., Salgado-Boquete L., Puig L., de la Cueva P., Carrascosa J.M.. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis [Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave]. Actas Dermo-Sifiliograficas. 2023; 114(6)DOI:10.1016/j.ad.2023.02.022. PMID:37172891. IF:(Q/D).